Rheumatoid arthritis
Conditions
Interventions
None listed
Sponsors
University of Occupational and Environmental Health, Japan
Department of Statistical Genetics, Osaka University Graduate School of Medicine, Osaka, Japan
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) RA patients satisfying the ACR/EULAR RA Classification Criteria 2010 2) Patients with RA poorly responding to treatment with one or more csDMARDs and having received no biopharmaceutical before 3) Patients aged 20 and over at the time of issuing consent to this study 4) Patients having begun to receive subcutaneous injection of abatacept on the basis of the attending physician's decision
Exclusion criteria
Exclusion criteria: 1) Patients with a history of allergy to any component of abatacept 2) Patients with complication by malignant tumor 3) Patients with active infection or hepatitis B and HB carrier 4) Pregnant women, lactating women or women desiring pregnancy, child delivery or breast-feeding 5) Patients judged as inappropriate for this study by Principal Investigator or Sub-investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Achievement rate of DAS28-CRP> 1.2 improvement 12 months after abatacept administration | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Identification of subgroups the patients according to their abnormality patterns in both SNP existence and baseline immune-phenotype profiles 2) Identification of patient subgroups for which abatacept is more efficacious | — |
Countries
Japan
Contacts
Public ContactShingo Nakayamada
University of Occupational and Environmental Health, Japan First Department of Internal Medicine
Outcome results
None listed